AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16140526
Drug: Amifostine administration
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amifostine administration
Trial: 14642140
Drug: L-thyroxine (L-T(50))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine (L-T(50))
Trial: 10430112
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg celecoxib twice a day
Trial: 10430112
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg naproxen twice a day
Trial: 7555513
Drug: 50/50 human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/50 human insulin mixture (0.3 U/kg)
Trial: 7555513
Drug: 70/30 human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70/30 human insulin mixture (0.3 U/kg)
Trial: 2188525
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine with 2.5 mg droperidol
Trial: 2188525
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine with placebo
Trial: 6457384
Drug: Needle acupuncture
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle acupuncture at correct sites according to Chinese medicine
Trial: 14722446
Drug: 10‐mg once‐daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg once‐daily topical regimen of miconazole nitrate mucoadhesive buccal tablet (n = 178)
Trial: 14722446
Drug: 400‐mg once‐daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400‐mg once‐daily systemic regimen of ketoconazole (n = 179)
Trial: 14722446
Drug: 10‐mg once‐daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg once‐daily topical regimen of miconazole nitrate mucoadhesive buccal tablet
Trial: 14722446
Drug: 400‐mg once‐daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400‐mg once‐daily systemic regimen of ketoconazole
Trial: 11095468
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol supplementation (TES); n = 10; Estraderm, 50 microg/24 h
Trial: 8250719
Drug: Hydrocortisone sodium
RxNorm normalized name: Hydrocortisone Sodium Phosphate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone sodium succinate (HCSS) 5 mg hydrocortisone/kg body weight
Trial: 8250719
Drug: Epinephrine (0.004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (0.004 mg/kg)
Trial: 3898836
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with carmustine, cyclophosphamide, and prednisone
Trial: 26867083
Drug: Therapist-guided internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-guided internet-based cognitive-behavioral treatment (iCBT)
Trial: 23488876
Drug: 3.57 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.57 ml/kg energy drink (ED)
Trial: 21774589
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg of elemental calcium with 400 IU vitamin D3
Trial: 16426291
Drug: Flutivate cream
RxNorm normalized name: fluticasone Topical Cream [Cutivate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutivate cream containing FA
Trial: 16426291
Drug: Betnovate cream
RxNorm normalized name: Betnovate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betnovate cream not containing FA
Trial: 11246305
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) high-dose treatment (6 g on day 1, 12 g on day 2, 18 g on days 3 and 4)
Trial: 11246305
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) high-dose treatment
Trial: 11246305
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (mucolytic basis dosage of NAC 3 x 300 mg/day)
Trial: 9038857
Drug: 0.025 mg
RxNorm normalized name: lisuride 0.025 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 mg rhGH/kg once daily
Trial: 9038857
Drug: rhIGF-I at
RxNorm normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIGF-I at 0.015 mg/kg twice daily (low dose)
Trial: 9038857
Drug: rhIGF-I at
RxNorm normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIGF-I at 0.03 mg/kg twice daily (mid dose)
Trial: 9038857
Drug: rhIGF-I at
RxNorm normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIGF-I at 0.06 mg/kg twice daily (high dose)
Trial: 9038857
Drug: mid dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mid dose rhIGF-I
Trial: 9038857
Drug: high dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose rhIGF-I
Trial: 2644150
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg t.i.d.)
Trial: 25909710
Drug: Mesna (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesna (360 mg/m2) co-administered with doxorubicin
Trial: 25909710
Drug: Saline co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline co-administered with doxorubicin
Trial: 24781527
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day erlotinib or a body weight-adjusted dose with subsequent escalations to 200 mg/day
Trial: 22366136
Drug: 0.5% chemically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% chemically modified lignin in diet contaminated with 7.9 mg/kg ZEA
Trial: 22366136
Drug: Diet contaminated
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet contaminated with 7.9 mg/kg ZEA
Trial: 22366136
Drug: 0.5% lignin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% lignin in diet contaminated with 7.9 mg/kg ZEA
Trial: 15696578
Drug: Etanercept (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (0.4 mg/kg) administered subcutaneously twice weekly for 6 months
Trial: 15696578
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously twice weekly for 6 months
Trial: 10501986
Drug: Topical miotics
RxNorm normalized name: nystatin / triamcinolone acetonide Topical Ointment [Myco Biotic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical miotics (n = 28)
Trial: 2592580
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg every 8 hours)
Trial: 3555370
Drug: Verapamil (drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (drug levels higher than 150 ng/ml)
Trial: 3555370
Drug: Verapamil (drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (drug levels lower than 150 ng/ml)
Trial: 29042456
Drug: Immunosuppressive combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive combination
Trial: 24935517
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and Propofol (sequential use)
Trial: 20552171
Drug: TFMPP 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFMPP 60 mg
Trial: 15917266
Drug: Extract of
RxNorm normalized name: Extract of tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract of Cajanus cajan (Ciklavit) administered twice daily for 6 months
Trial: 15917266
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily for 6 months
Trial: 8731235
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg etodolac b.i.d for three days after a 36-hour placebo washout
Trial: 8731235
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg indomethacin b.i.d for three days after a 36-hour placebo washout
Trial: 8298199
Drug: ALN 10
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN 10 mg daily
Trial: 8298199
Drug: ALN 20
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN 20 mg daily
Trial: 8298199
Drug: CT 100
RxNorm normalized name: B-Ject 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT 100 IU daily
Trial: 3080510
Drug: Astemizole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (10 mg every day)
Trial: 27442155
Drug: Low-dose inhaled
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose inhaled nitric oxide (iNO) starting at 5 parts per million, maintenance dose of 2 parts per million for ⩾7 days (n=162)
Trial: 24337471
Drug: Expanded School
RxNorm normalized name: schorl tourmaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expanded School Mental Health (ESMH) treatment
Trial: 22985572
Drug: Remifentanil 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.05 µg·kg(‐1)·min(‐1)
Trial: 22985572
Drug: Remifentanil 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.10 µg·kg(‐1)·min(‐1)
Trial: 22985572
Drug: Remifentanil 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.20 µg·kg(‐1)·min(‐1)
Trial: 22985572
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug (Control group D)
Trial: 20637962
Drug: Banana-flavored suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Banana-flavored suspension
Trial: 10687570
Drug: Daily smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily smoking relapse postpartum
Trial: 1897811
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray 200 micrograms QD
Trial: 1897811
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray 100 micrograms BID
Trial: 6291802
Drug: Clonidine, 0.3
RxNorm normalized name: Clonidine, 0.3 mg/24 hr transdermal film, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine, 0.3 mg/day orally for 3 days
Trial: 6291802
Drug: Naloxone, 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone, 0.4 mg intravenously on the third day of clonidine treatment
Trial: 26365823
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D auxiliary rehabilitation therapy
Trial: 26179090
Drug: GSK2374697 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2374697 2 mg
Trial: 24368086
Drug: Single vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vaccination with rHVT‐ND vaccine at one day of age
Trial: 24368086
Drug: Single vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vaccination with rHVT‐ND vaccine
Trial: 24368086
Drug: Booster vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster vaccination of rHVT‐ND vaccinated birds with conventional ND vaccines
Trial: 23866474
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (5 g/kg)
Trial: 17513652
Drug: parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: parecoxib 40 mg at induction, placebo at wound closure, parecoxib 40 mg 12 h after induction (pre)
Trial: 17513652
Drug: placebo at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo at induction, parecoxib 40 mg at wound closure, parecoxib 40 mg 12 h after induction (post)
Trial: 15378186
Drug: Intrarectal amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal amifostine (1,500 mg in a 40-ml enema)
Trial: 11744585
Drug: Preemptive analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive analgesia (multi-modal therapy)
Trial: 9850014
Drug: Single-agent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent therapy
Trial: 9852695
Drug: Propofol (P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (P group) - 2.5 mg.kg‐1 with 0.2 microgram.kg‐1 fentanyl
Trial: 4712484
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine with propanidid
Trial: 30992200
Drug: Cinnamomum zeylanicum
RxNorm normalized name: Cinnamomum camphora resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamomum zeylanicum extract at 4 mg/mL
Trial: 30992200
Drug: Cinnamomum zeylanicum
RxNorm normalized name: Cinnamomum camphora resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamomum zeylanicum extract at 2 mg/mL
Trial: 18804330
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (40 I.U.)
Trial: 1340550
Drug: Subcutaneous salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous salbutamol (0.5 mg)
Trial: 31437695
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg ketamine (standard dose)
Trial: 31437695
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg ketamine (low dose)
Trial: 29794060
Drug: Bilateral deep
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral deep brain stimulation (DBS) targeting the anterior limb of the internal capsule in nondiabetic patients.
Trial: 29794060
Drug: Optogenetic activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optogenetic activation of dopamine D1 receptor-expressing neurons in the nucleus accumbens in mice.
Trial: 25348346
Drug: Integrated care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated care including treatment as usual plus a psychoeducational intervention (14 sessions)
Trial: 25348346
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (pharmacotherapy and regular sessions with psychiatrist)
Trial: 17631702
Drug: rhGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH treatment (10 U hypodermically daily for 10 days)
Trial: 29316154
Drug: Oral nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine (n=71)
Trial: 29316154
Drug: Intravenous labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous labetalol (n=72)
Trial: 27590259
Drug: Riociguat (Adempas®,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat (Adempas®, BAY 63‐2521) administered over 26 weeks
Trial: 22361121
Drug: Gaviscon® (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaviscon® (4 × 10 mL/day)
Trial: 17644123
Drug: Local therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local therapy for select patients with increasing PSA values below 1.0 ng/ml and lower Gleason score neoplasms.
Trial: 7542675
Drug: Loratadine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (20 mg)
Trial: 347569
Drug: Valproate with
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate with reduced phenobarbital dose (by about 40%)
Trial: 30964527
Drug: Standard-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose vitamin D3
Trial: 26172084
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 U/ml (Gla-100)
Trial: 14687141
Drug: Nurse-administered propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered propofol
Trial: 2444307
Drug: Bromocriptine 2.5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 mg and 5 mg
Trial: 28414488
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for Self-Injurious Behaviors (T-SIB); n = 15
Trial: 28414488
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual; n = 18
Trial: 16418308
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) 850 mg/m2 intravenously every 4 weeks
Trial: 16418308
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) chemotherapy
Trial: 7955182
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus antithrombin III (250 U heparin + 25 U antithrombin III per minute)
Trial: 7955182
Drug: Heparin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin alone (250 U heparin per minute)
Trial: 7955182
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus antithrombin III
Trial: 23772532
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of low-dose remifentanil (0.02, 0.05, and 0.07 microg x kg ‐1 x hr‐1)
Trial: 23772532
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of low-dose remifentanil
Trial: 18979547
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m2, i.v. infusion for 3 consecutive weeks followed by 1-week rest)
Trial: 12195873
Drug: Pivmecillinam 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 400 mg b.i.d.
Trial: 8040170
Drug: Balanced analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced analgesic regime with NSAID and continuous extrapleural intercostal nerve block
Trial: 23204039
Drug: control (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control (topical therapies or phototherapy)
Trial: 16974199
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg GHB (Xyrem)
Trial: 9051093
Drug: G‐CSF, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF, 300 micrograms subcutaneously
Trial: 9051093
Drug: G‐CSF, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF, 600 micrograms subcutaneously
Trial: 9051093
Drug: Dexamethasone, 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone, 8 mg orally
Trial: 9051093
Drug: G‐CSF, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF, 300 micrograms subcutaneously plus dexamethasone, 8 mg orally
Trial: 9051093
Drug: G‐CSF, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF, 600 micrograms subcutaneously plus dexamethasone, 8 mg orally
Trial: 9051093
Drug: Dexamethasone (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (any dose)
Trial: 8312118
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy (BEP)
Trial: 8312118
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy with irradiation
Trial: 8312118
Drug: Extended field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended field irradiation with weekly cisplatin
Trial: 8312118
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy prior to pelvic radiotherapy
Trial: 31549519
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and exercise (MET)
Trial: 21930719
Drug: Improved antihypertensive
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved antihypertensive treatment
Trial: 18426345
Drug: Ertapenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem (1 g)
Trial: 16551150
Drug: Positive therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive therapeutic relationship early in treatment
Trial: 1388091
Drug: Etodolac 300
RxNorm normalized name: etodolac 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 300 mg TID (900 mg/day)
Trial: 1388091
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg BID (1000 mg/day)